Professor David Fairlie

NHMRC Snr Principal Research Fellow

Institute for Molecular Bioscience

Affiliated Professor

School of Chemistry and Molecular Biosciences
Faculty of Science
d.fairlie@imb.uq.edu.au
+61 7 334 62989
+61 7 334 62381

Overview

Professor Fairlie was appointed as Head of IMB’s Chemistry and Structural Biology Division in 2009. He is one of a team of ten IMB group leaders and four division affiliates working across the disciplines of chemistry, biochemistry and pharmacology.

Professor Fairlie completed his undergraduate studies at The University of Adelaide, postgraduate studies at Australian National University and The University of New South Wales, and postdoctoral studies at Stanford University and The University of Toronto. He has held Australian Research Council(ARC) Federation and Professorial fellowships and chief scientific officer and scientific director roles in leading scientific companies. He has also collaborated with some of the world’s largest biopharmaceutical companies.

Professor Fairlie is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow.

Research Interests

  • General Information: Chemistry and Human Therapeutics
    We use state of the art methods to invent new compounds that regulate enzymes, cellular receptors, RNA or DNA. Techniques include solution and solid phase organic synthesis, coordination/organometallic chemistry, parallel synthesis methodologies, computer modelling, 2D-NMR spectroscopy. Some members of the group are also involved in enzyme and cellular assays, protein expression, target validation, and structure determination by NMR spectroscopy and X-ray crystallography. For our drug discovery projects we collaborate daily with pharmacologists, virologists, cancer biologists, neurobiologists and structural biologists to study compounds in models of human disease (inflammation, viral and parasitic infections, cancer, Alzheimer's disease). Overall we are interested in elucidating the mechanisms of chemical reactions, biological processes, disease development and drug action. We only work with chemicals and proteins - these are safe - research with live viruses or infectious agents is carried out by our collaborators.
  • Chemical Synthesis, Structure and Mechanism
    Our principal thrust is chemistry and involves the design of new molecules, the development of new methods to make them, the determination and analysis of their structures, mechanistic investigations of their reactivities, and the use of small molecules to probe biological processes and to elucidate relationships between chemical structure and disease regulation. In 2000 we used a wide range of solution and solid phase organic synthesis methodologies to synthesize bioactive molecules (e.g. de novo designed drugs, natural product analogues, and peptidomimetics), reactive intermediates, highly functionalised molecular templates, structural constraints, and artificial receptors. We also synthesized metal complexes as folding templates, as catalysts for organic reactions, and as models of metalloproteins. We are engaged in chemical design and structural analysis using computers, determination of chemical structures by NMR spectroscopy and X-ray crystallography, spectroscopic investigations of chemical and biological reactions, enzyme kinetics, cell biology, and molecular pharmacology in vitro and in vivo.
  • Protein Surface Mimics (Technology Platforms)
    A key strategic objective is to develop small organic molecules to mimic bioactive protein surfaces that are recognized by other proteins-, DNA- or RNA- during disease processes. We have identified conformations of protein surfaces that are common recognition elements for protease enzymes, for classes of G protein-coupled receptors, or for transcriptional receptors. We now have small molecules that structurally and functionally mimic bioactive protein surfaces including beta strands (funded by ARC), beta-sheets (funded by NHMRC), beta and gamma turns (NHMRC), alpha helices (ARC), helix bundles, and multi-loop bundles. There are numerous potential uses for each of these classes of small molecule protein surface mimics - this is why we are able to investigate so many therapeutic applications. To date our evolving technologies have led us to inhibitors of proteases (involved in almost all disease processes), antagonists and agonists of G protein-coupled receptors that span cell membranes and mediate cell signalling, inhibitors that interfere with aggregation of proteins and peptides, and mimics of discontinuous peptide surfaces that closely approach one another in proteins but originate from different or non-contiguous surfaces. We have already demonstrated that some of these mimetics are orally active anti-inflammatory, anti viral or anti tumour agents. The work involves computer-assisted molecular design, chemical synthesis, structure determination (using NMR, crystallography, CD, MS), and in vitro and in vivo assays used to demonstrate proof of concept.
  • Helical Peptidomimetics
    Small peptide fragments corresponding to helical domains of proteins are usually unstructured in solution away from the structure-stabilizing environment of proteins. If short helical units could be stabilised they might have many important uses as tools in biology and drugs in medicine. In an ARC-funded project we have investigated one promising strategy for constraining short peptides into alpha helical structures using simple metal clips like Pd(en)2+. We constrained the pentapeptide HAAAH into the first characterised NMR structure of a single turn of an alpha helix. This works by coordination of two imidazoles to Pd, enforcing intramolecular peptide hydrogen bonds. We successfully used such metal clips on the ends, and within, 10-15 residue fragments of metalloproteins like thermolysin to induce alpha helicity, the short peptides alone having no structure. We are now investigating effects of different metal ions, ligands, peptide side chains, and different chelating donor atoms on helix induction in biologically important peptides and protein fragments. We have also been designing and synthesising small organic molecules as templates to nucleate peptide helices from the N-terminus, from the C-terminus, from both ends, and from within a peptide sequence. The main problem encountered has been competition from alternative intramolecular hydrogen bonding atoms leading to formation of smaller gamma and beta turns rather than the larger alpha helical turns that make up alpha helices. The solution to these problems is to use large, conformationally rigid linkers leading to macrocycles that are conformationally constrained into 13-membered hydrogen bonded alpha turns. This work has involved extensive 2D NMR and CD spectral studies to identify solution structures and determine folding energetics. We are now mimcking biologically important alpha helical peptides with our more conformationally and metabolically stable peptidomimetics.
  • Molecular Recognition
    We are especially interested in how molecules (non-covalently) interact with one another. This involves the use of a wide variety of spectroscopic and structural techniques (NMR & EPR spectroscopy, mass spectrometry, X-ray crystallography, analytical ultracentrifugation, CD, UV-Vis, IR, fluorescence, polarimetry, plasmon resonance). We are examining small molecules that bind to peptides, proteins, RNA, DNA, and metal ions and are assessing the contributions of specific interactions to the entropy and enthalpiy of chemical and biological reactions. We have also been creating novel supramolecular structures (20� to 500 nm in size) that could be the forerunners to artificial enzymes and catalysts. These include combinations of macrocycles as membranes/monolayers, as templates for protein surface mimetics, as ion channels, and in cylindrical and conical cavitands as hydrophobic chambers in which to conduct catalytic reactions. In some cases we have investigated self assembly of supramolecular beta sheet structures to form nanomaterials that include fibers and tubes. The chemical properties of such artificial systems can be very useful in understanding how to engineer new materials and how macromolecular biomolecules function. They can have many industrial applications.
  • Natural Product Analogues
    Another source of our bioactive lead compounds has come from studies of the chemistry of certain classes of natural products. For example, from plants we have previously studied classes of quinolines, isoquinolines, flavonoids as antiinflammatory or antiviral agents. From tunicates and sea cucumbers from the Great Barrier Reef we have been examining compounds that contain unusual constraints that profoundly influence the three dimensional structures of the molecules. From sea cucumbers we identified antiinflammatory properties and from ascidia we have studied cytotoxic compounds with antitumour activities. We used this latter class of compounds to generate new molecules that adopt the largest "chair" and "boat" conformations known in the chemical world and this inspired us to recently produce novel libraries of chemical scaffolds up to 100� in size. Currently we are using parallel synthesis strategies to generate libraries of natural product analogues.
  • Alzheimer's Disease
    In one project (funded by the Australian Research Council) we have been examining the origin of free radicals reportedly produced by beta amyloid peptide, a 42 residue peptide that is the chief constituent of the amyloid plaques found at autopsy in the brains of Alzheimer's sufferers. Early experimental work has involved NMR and EPR spectroscopy, CD, Sedimentation Equilibria, computer modelling and peptide synthesis. Recently we developed a theory for the generation of these radicals and have been testing it experimentally for several years. Preliminary results have suggested novel strategies for the design and development of drugs for this increasingly prevalent disease. In a second project (funded by the National Health and Research Council of Australia) we synthesized the first sub-micromolar inhibitors of beta secretase, an enzyme responsible for producing beta amyloid peptide. In November 1999, several pharmaceutical companies revealed that this enzyme is an aspartic protease (the same class as HIV-1 protease above). Using our substantial experience with protease inhibitor design, synthesis and testing, we are working towards the development of a promising treatment for Alzheimer's disease which currently has no effective treatment.
  • Inflammation
    We are working on a number of projects that aim to design, synthesize and test small non-peptidic molecules which inhibit enzymes or antagonize cellular receptors that mediate inflammatory responses. At present we have several classes of compounds (designed using structure-based approaches) that are orally active at doses at or below 1mg/kg given once in acute inflammatory diseases or once daily in chronic inflammatory diseases to rats, mice or other animals. Two examples are :
  • Inhibitors of Human Secretory Phospholipases A2 (Funded by NHMRC). We are using computer-assisted inhibitor design, crystal structures of these enzymes bound to small molecules, non-peptidic 'classical' oraganic synthesis, a simple colorimetric enzyme assay, and some pharmacological assays in rats to investigate the potential of selective sPLA2 inhibitors as antiinflammatory agents. Despite enormous research effort during the past 20 years in this field there are actually only a handful of bona fide potent inhibitors known (including our own), due to misleading assays and past problems associated with obtaining human enzymes. We have already shown proof of principle - that such inhibitors have demonstrable therapeutic effects in a variety of animal models of human diseases and we predict that this field will quickly reemerge in the light of the recent spectacular success of the latest anti-inflammatory drugs (e.g. COX-2 inhibitors) that are really quite limited compared with new sPLA2 inhibitors.
  • Agonists/Antagonists of C5a Receptors (Funded by NHMRC). C5a is a 74 residue "Complement" protein which is synthesized in human blood in response to infection. It has long been known that this "anaphylatoxin" is upregulated in most inflammatory diseases and is thought to be a crucial mediator in such diseases. Until our work there was no 'pure' small molecule antagonist available to confirm the role of this protein in human immune defence. The interaction between C5a (in the blood) and its receptor on the surface of numerous types of cells leads to production of many cytokines and inflammatory mediators which contribute to autoimmune and inflammatory diseases such as rheumatoid arthritis, lupus, atherosclerosis, multiple sclerosis, fibrosis, sepsis, asthma, ischemia and reperfusion injury and at least 20 other inflammatory conditions. Through NHMRC funding we investigated cyclic peptide antagonists of the human C5a receptor on neutrophils and macrophages. These compounds showed oral activity at less than or equal to 1mg/kg in rats/dogs, completely blocking formation of inflammatory cytokines like tumour necrosis factor alpha and interleukins 1 and 6, and potently inhibit several inflammatory diseases. We have since been constructing potent and selective new non-peptidic antagonists with improved pharmacokinetic and pharmacodymaic properties as prospective anti-inflammatory drugs. Many more inflammatory disease indications are also being examined for their susceptibility to C5a antagonists which appear to be a very promising new class of antiinflammatory drugs that act early in the inflammatory network.
  • Viral and Parasitic Infections
    These projects all involve chemical and biochemical studies of drugs that interact with viral or parasitic proteins (which are safe to handle). Chemistry is the engine that creates our bioactive compounds in house and these are then evaluated in house using enzyme kinetics for their ability to inhibit enzymes. Subsequently potent and selective compounds are tested with collaborators in Australia and overseas. Projects include:
  • HIV REV (Funded by NHMRC). We are developing inhibitors of REV, an HIV protein that binds to mRNA in the nucleus of an HIV-infected cell and helps to export it to the cytoplasm. Rev binds to RNA via a 17 amino acid arginine-rich component which we showed to be alpha-helical in 1995. We have since developed assays to measure inhibition of this process, expressed REV, and designed some initial small molecule inhibitors which (if successful) are expected to prevent viral replication.
  • HIV-1 Protease (Funded by NHMRC). We have developed a large number of inhibitors of this enzyme which is important in the generation of structural and non-structural HIV proteins required for viral replication/maturation. An important problem that we have been addressing is the genaration of inhibitors to which the virus either cannot, or only with great difficulty, become resistant. Preliminary results have been very encouraging and our method for overcoming resistance has the potential to be applied to many other diseases where drug resistance is a major problem.
  • Dengue Virus (Funded By NHMRC). Based on the crystal structure of a serine protease involved in replication of this virus we are designing non-peptidic inhibitors that can potentially be developed into effective drugs for dengue infections, a mosquito borne virus that infects millions of people in mainly tropical countries. Most of the work to date has focussed on characterising the kinetic properties of the enzyme, which needs a cofactor for processing, and expressing protease for cocrystallization with initial inhibitors. We are determining crystal structures for the protease in the presence of inhibitors and cofactor, and developing potent antiviral agents tested in cell culture.
  • Schistosomiasis (Funded by NHMRC). This is the largest parasitic killer of humans after malaria. In collaboration with QIMR we have been testing very potent compounds developed in our labs to inhibit (at nanomolar concentrations) schistosomal proteases. These proteases are thought to be important to schistosomes that feed on human blood by proteolytically cleaving and then digesting hemoglobin. This work is aimed at discriminating between these worm proteases and closely analogous human proteases that are required for normal physiological functions. We are studying crystal structures of these proteases bound to small molecule inhibitors developed in our labs.
  • Malaria and Giardia : see Cancer below.
  • Cancer
    Our principal interests in cancer focus on developing small non-peptidic molecules that selectively kill cancer cells without being toxic to normal cells. One target for which we have developed and patented effective agents is histone deacetylase, a transferase enzyme that removes acetyl groups from acetylated lysines. This project lends itself to combinatorial methods of analoguing as we already know what we wish to optimise for in the chemical structures of our inhibitors. Inhibitors have proven to be effective in a very wide range of human tumour cell lines (potency at nanomolar concentrations) as well as in mice bearing xenografts of human tumours. We seek to better understand the basis for the selective actions of our drugs, to extend the potential of these compounds not only to cancer but also to other infections in which growth needs to be halted (e.g. malaria, giardia), and to further our structure-activity relationships with the aid of computer modelling studies and NMR-derived inhibitor structures.

Research Impacts

Our researchers work at the interface of chemistry and biology to better understand the molecular mechanisms of life, ageing, disease and death.

Our chemists study medicinal chemistry, organic synthesis, and computer-aided drug design; use nuclear magnetic resonance (NMR) spectroscopy to investigate the structure and dynamics of proteins; and learn how small molecules interact with other small molecules, proteins, RNA and DNA. They discover new chemical structures, reactions and mechanisms; enzyme inhibitors, agonists and antagonists; and molecules that mimic the structures and functions of bioactive protein surfaces.

Our biologists use these novel compounds to explain the functions of human proteins and cells, and apply them to treat animal models of human diseases. They study mechanisms of protein and cell activation, biological processes, disease development and drug action.

Scientists within our laboratory combine their expertise across these fields to gain insights into human physiology and disease pathology, and develop skills in biochemistry, pharmacology, virology, immunology, oncology or neurobiology. They are working, in some cases with industry partners, to discover new drugs and treatments for: viral and parasite infections, such as HIV, dengue fever and malaria; inflammatory diseases, such as arthritis and inflammatory bowel disease; metabolic and cardiovascular diseases resulting from obesity and type 2 diabetes; cancers; and neurological diseases, such as Alzheimer’s and stroke.

Qualifications

  • PhD, University of New South Wales
  • BSc(Hons), The University of Adelaide

Publications

  • Baxter, Daniel, Perry, Samuel R., Hill, Timothy A., Kok, W. Mei, Zaccai, Nathan R., Brady, R. Leo, Fairlie, David P. and Mason, Jody M. (2017) Downsizing proto-oncogene cFos to short helix-constrained peptides that bind Jun. ACS Chemical Biology, 12 8: 2051-2061. doi:10.1021/acschembio.7b00303

  • Ward, Ambber, Dong, Lilong, Harris, Jonathan M., Khanna, Kum Kum, Al-Ejeh, Fares, Fairlie, David P., Wiegmans, Adrian P. and Liu, Ligong (2017) Quinazolinone derivatives as inhibitors of homologous recombinase RAD51. Bioorganic & Medicinal Chemistry Letters, 27 14: 3096-3100. doi:10.1016/j.bmcl.2017.05.039

  • Nielsen, Daniel S., Shepherd, Nicholas E., Xu, Weijun, Lucke, Andrew J., Stoermer, Martin J. and Fairlie, David P. (2017) Orally absorbed cyclic peptides. Chemical Reviews, 117 12: 8094-8128. doi:10.1021/acs.chemrev.6b00838

View all Publications

Supervision

  • Doctor Philosophy

  • Doctor Philosophy

  • Doctor Philosophy

View all Supervision

Publications

Book Chapter

  • Mak, Jeffrey Y. W., Xu, Weijun and Fairlie, David P. (2017). Thiazoles in peptides and peptidomimetics. In William D. Lubell (Ed.), Peptidomimetics I (pp. 235-266) Cham, Switzerland: Springer. doi:10.1007/7081_2015_176

  • Lohman, Rink-Jan, Harrison, Rosemary S., Ruiz-Gomez, Gloria, Hoang, Huy Ngoc, Shepherd, Nicholas E., Chow, Shiao, Hill, Timothy A., Madala, Praveen K. and Fairlie, David P. (2015). Helix-constrained nociceptin peptides are potent agonists and antagonists of ORL-1 and nociception. In Gerald Litwack (Ed.), Nociceptin opioid (pp. 1-55) Maryland Heights, MO, United States: Academic Press. doi:10.1016/bs.vh.2014.10.001

  • Loughlin, Wendy A. and Fairlie, David P. (2011). Recent advances in β-Strand mimetics. In Andrew B. Hughes (Ed.), Amino acids, peptides and proteins in organic chemistry: protection reactions, medicinal chemistry, combinatorial synthesis (pp. 129-147) Somerset, NJ, United States: Wiley-VCH. doi:10.1002/9783527631827.ch3

  • Hans, Dhiraj, Young, Paul R. and Fairlie, David P. (2009). Tumor-associated antigenic peptides as vaccine candidates. In Olivier Gires and Barbara Seliger (Ed.), Tumor-associated antigens (pp. 303-316) Weinheim, Germany: Wiley - VCH Verlag.

  • Reid, Robert, C. and Fairlie, David P. (2008). Parallel synthesis af anticancer, antiinflammatory and antiviral agents derived from L- and D- amino acids. In Tushar Kshirsagar (Ed.), High-throughput lead optimisation in drug discovery (pp. 177-194) Boca Raton, USA: CRC Press.

  • Harrison, R. S., Sharpe, P. C., Singh, Y. and Fairlie, D. P. (2007). Amyloid peptides and proteins in review. In S. G. Amara, B. Bamberg, T. Fleischmann, S. C. Gudermann, S. C. Hebert, R. Jahn, W. J. Lederer, R. Lill, A. Miyajima, S. Offermanns and R. Zechner (Ed.), Reviews of physiology, biochemistry and pharmacology (pp. 1-77) Berlin, Germany: Springer. doi:10.1007/112_2007_0701

  • Taylor, S. M. and Fairlie, D. (2005). Discovery of Potent Cyclic Antagonists of Human C5a Receptors. In I. Morikis and J Lambris (Ed.), Structural Biology of the Complement System (pp. 341-362) New York: CRC Press, Taylor and Francis.

  • Kelso, M. J. and Fairlie, D. (2003). Current approaches to peptidomimetics. In I. Toth and G. Keri (Ed.), Molecular Pathomechanisms and New Trends in Drug Research (pp. 579-598) London and New York: Taylor and Francis.

  • Fairlie, D. P. and Reid, R. C. (1997). Mimicking extended conformations of protease substrates: Designing cyclic peptidomimetics to inhibit HIV-1 protease. In Advances in amino acid mimetics and peptidomimetics (pp. 77-107) London: JAI Press Inc.

Journal Article

Conference Publication

  • Gherardin, N. A., Keller, A. N., Woolley, R. E., Le Nours, J., Ritchie, D. S., Neeson, P. J., Birkinshaw, R. W., Eckle, S. B., Waddington, J. N., Liu, L., Fairlie, D. P., McCluskey, J., Pellicci, D. G., Uldrich, A. P., Rossjohn, J. and Godfrey, D., I (2016). A broad family of MR1-restricted T cells. In: International Congress of Immunology (ICI), Melbourne Australia, (153-154). 21-26 August 2016.

  • Keller, A. N., Eckle, S. B. G., Xu, W., Liu, L., Hughes, V. A., Mak, J., Meehan, B., Pediongco, T., Birkinshaw, R. W., Chen, Z., Wang, H., Souza, C., Kostenko, L., Corbett, A. J., Purcell, A. W., Fairlie, D. P., McCluskey, J. and Rossjohn, J. (2016). Common drugs modulate mucosal-associated invariant T cell function. In: International Congress of Immunology (ICI), Melbourne, VIC, Australia, (257-257). 21-26 August 2016. doi:10.1002/eji.201670200

  • Eckle, S. B. G., Keller, A. N., Xu, W., Meehan, B., Pediongco, T., Liu, L., Hughes, V. A., Mak, J. Y. W., Birkinshaw, R. W., Chen, Z., Wang, H., D'Souza, C., Kostenko, L., Corbett, A. J., Purcell, A. W., Fairlie, D. P., Rossjohn, J. and McCluskey, J. (2016). Drugs/drug analogues modulate MAIT cell function in an MR1-dependent manner. In: International Congress of Immunology (ICI), Melbourne, VIC, Australia, (587-587). 21-26 August 2016. doi:10.1002/eji.201670200

  • McCluskey, J., Corbett, A. J., Eckle, S. B. G., Chen, Z., Wang, H., Sun, S., D'Souza, C., Kostenko, L., Reantragoon, R., Meehan, B., Birkinshaw, R. W., Liu, L., Patel, O., Mahony, J., Cao, H., Jackson, D., Williamson, N. A., Strugnell, R. A., Mak, J. Y. W., Van Sinderen, D., Fairlie, D. P., Kjer-Nielsen, L., Godfrey, D., I and Rossjohn, J. (2016). MAIT cells: Friend or Foe in recognising microbial vitamin metabolites presented by the MHC-I-related molecule MR1. In: International Congress of Immunology (ICI), Melbourne, Australia, (796-797). Aug 21-26, 2016. doi:10.1002/eji.201670200

  • Tesch, G., Han, Y., Vesey, D., Gobe, G., Lohman, R., Suen, J., Fairlie, D. and Nikolic-Paterson, D. (2016). Pharmacological Inhibition of Protease-Activated Receptor 2 (Par2) Reduces Crescent Formation in Rat Anti-Gbm Disease. In: Unknown, Unknown, (83-83). Unknown.

  • Owens, E., Iyer, A., Morais, C., Lohman, R., Suen, J., Johnson, D., Nikolic-Paterson, D., Gobe, G., Fairlie, D. and Vesey, D. (2016). Protease activated-receptor-2 induced inflammation and fibrosis is mediated in part through activation of transforming growth factor-beta signalling. In: Unknown, Unknown, (86-86). Unknown.

  • Godfrey, D., Koay, H. -F, Gherardin, N., Enders, A., Loh, L., Chen, Z., Corbett, A., Eckle, S., Meehan, B., d'Udekem, Y., Konstantinov, I, Lappas, M., Liu, L., Goodnow, C., Fairlie, D., Rossjohn, J., Kedzierska, K., Berzins, S., McCluskey, J., Uldrich, A. and Pellicci, D. (2016). Thymic precursors to the mucosal-associated invariant T cell lineage. In: International Congress of Immunology (ICI), Melbourne Australia, (256-257). 21-26 August 2016.

  • Fairlie, David P. , Yau, Mei-Kwan , Hamidon, Johan K. , Singh, Ranee , Lim, Junxian , Suen, Jacky Y. , Rowley, Jessica A. , Lohman, Rink-Jan , Stoermer, Martin J. , Iyer, Abishek and Reid, Robert C. (2015). Downsizing Proteins Without Losing Potency or Function. In: Ved Srivastava, Andrei Yudin and Michal Lebl, Proceedings of the 24th American Peptide Symposium. American Peptide Symposium 2015, Orlando , Florida, United States, (). 20-25 June 2015. doi:10.17952/24APS.2015.016

  • Hung Nguyen, Heinrichs, Jessica Lauren, Fu, Jianing, Wu, Yongxia, Bastian, David, Schutt, Steven, Daenthanasanmak, Anusara, Dany, Mohammmed, Liu, Chen, Fairlie, David, Tomlinson, Stephen and Yu, Xue-Zhong (2015). Targeting Host Complement C3a/C5a Receptors to Control of Acute Graft-Versus-Host Disease in Mice. In: 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, (). 5-8 December 2015.

  • Sakala, Isaac G., Kjer-Nielsen, Lars, Eickhoff, Christopher S., Wang, Xiaoli, Liu, Ligong, Fairlie, David P., Rossjohn, Jamie, McCluskey, James, Hoft, Daniel F. and Hansen, Ted H. (2015). Tetramer identification of functional mouse mucosal associated invariant T (MAIT) cells. In: 8th International Workshop on Antigen Processing and Presentation, Philadelphia Pa, (143-144). Jun 10-13, 2014.

  • Chow, Shiao Yun, Stoermer, Martin J., Chappell, Keith J., Young, Paul R. and Fairlie, David P. (2013). Novel inhibitors of DENV NS2B/NS3pro protease. In: Abstracts of Papers of the American Chemical Society. 246th National Meeting of the American-Chemical-Society (ACS), Indianapolis in, (). Sep 08-12, 2013.

  • Duprez, W., Lakshmanane, P., Kurth, F., Bachu, P., Halili, M., Cooper, M., Scanlon, M., Fairlie, D. P. and Martin, J. L. (2013). Inhibiting Virulence in E. coli: Screening of Peptidomimetics Ttargeting the DsbA Disulfide Bond Formation Machinery. In: Biopolymers. 23rd American Peptide Symposium, Waikoloa Hi, (302-302). Jun 22-27, 2013.

  • Cantley, M., Fairlie, D., Bartold, M., Marino, V, Gupta, P. and Haynes, D. (2013). Targeting Histone Deacetylase 1 (Hdac 1) to Suppress Both Inflammation and Bone Loss in Arthritis. In: Special Issue: Australian Rheumatology Association in conjunction with the Rheumatology Health Professionals Association 54th Annual Scientific Meeting: Conference Abstracts. 54th Annual Scientific Meeting of the Australian Rheumatology Association in conjunction with the Rheumatology Health Professionals Association, Perth, WA Australia, (1-1). 18 -22 May 2013. doi:10.1111/imj.12139

  • Barbero, Sheila, Reid, Robert C., Stoermer, Martin J., Lohman, Rink J. and Fairlie, David P. (2013). Toward more orally bioavailable inhibitors of phospholipase A(2) GIIA (pla2g2a) to treat chronic inflammation. In: Abstracts of Papers of the American Chemical Society. 246th National Meeting of the American-Chemical-Society (ACS), Indianapolis, IN, United States, (). 8-12 September 2013.

  • Diness, Frederik, Begtrup, Mikael Begtrup and Fairlie, David P. (2012). Fluorobenzene derivatives as multifunctional tools. In: Abstracts of Papers of the American Chemical Society. 243rd National Spring Meeting of the American-Chemical-Society, San Diego Ca, (). Mar 25-29, 2012.

  • Croker, Daniel E., Halai, Reena, Fairlie, David P. and Cooper, Matthew A. (2012). Ligand-induced dimerisation of the complement C5aR and C5L2 receptors by C5a but not C5a-des Arg. In: Immunobiology. XXIV International Complement Workshop (ICW), Crete, Greece, (1181-1182). 10-15 October 2012. doi:10.1016/j.imbio.2012.08.152

  • Theodossis, Alex, Ruiz-Gomez, Gloria, Gibb, Andrew, Welland, Andrew, Jones, Paul, Fairlie, David and Rossjohn, Jamie (2012). Shedding light on MHC class I antigen loading: A UV-labile peptide ligand approach. In: Abstracts: 7th International EMBO Workshop on Antigen Presentation and Processing. 7th International EMBO Workshop on Antigen Presentation and Processing, Amsterdam, Netherlands, (33-33). 24-27 April 2012. doi:10.1016/j.molimm.2012.02.094

  • Theodossis, A., Ruiz-Gomez, G., Gibb, A., Welland, A., Jones, P., Fairlie, D. and Rossjohn, J. (2012). Shedding light on MHC class I antigen loading: a UV-labile peptide ligand approach. In: Proceedings of the 32nd European Peptide Symposium. 32nd European Peptide Symposium "Peptides 2012", Athens, Greece, (S27-S27). 02-07 September 2012. doi:10.1002/psc.2447

  • Cantley, M. D., Fairlie, D. P., Bartold, P., Marino, V. and Haynes, D. R. (2011). Inhibiting Histone Deacetylases Expressed in Human Periodontal Tissues Prevents Bone Loss in An Animal Model of Periodontal Disease. In: Osteoporosis International. IOF Regionals 2nd Asia-Pacific Osteoporosis and Bone Meeting / ANZBMS Annual Scientific Meeting held with the JSBMR, Gold Coast Australia, (S613-S613). Sep 04-08, 2011.

  • Yau, Annika M., Liu, Ligong, Reid, Robert C., Barry, Grant D., Suen, Jacky Y., Lohman, Rink-Jan, Le, Giang T., Cotterell, Adam and Fairlie, David P. (2011). Novel agonists and antagonists for protease activated receptor 2. In: Abstracts of Papers of the 242nd National Meeting of the American Chemical Society. National Meeting of the American Chemical Society (242nd, ACS, 2011), Denver, CO, U.S.A., (). 28 August-1 September 2011.

  • Fairlie, David P., Stoermer, Martin, Lucke, Andrew, Lohman, Rink-Jan, Liu, Ligong and Ruiz-Gomez, Gloria (2011). Towards orally bioavailable peptides and peptidomimetics. In: Abstracts of Papers of the American Chemical Society. 241st National Meeting and Exposition of the American-Chemical-Society (ACS), Anaheim, CA, United States, (). 27-31 March 2011.

  • Holt, J. R., Monk, P. N., Fairlie, D. P. and Madala, P. Kumar (2010). Modelling of the C5a receptor by iterative mutation. In: Molecular Immunology. 23rd International National Complement Workshop, New York Ny, (2215-2216). Aug 01-05, 2010. doi:10.1016/j.molimm.2010.05.061

  • Vesey David A., Suen, Jacky Yung, Johnson, David W. and Fairlie, David (2010). A Novel Protease-Activated Receptor-2 Antagonist Targeting Inflammation and Proliferation in Human Renal Tubular Epithelial Cells. In: Kidney Week, American society of Nephrology, Denver Colorado USA, (78-78). November 16 - 21.

  • Vesey, D., Rajandram, R., Blakeney, J., Suen, J., Johnson, D., Fairlie, D. and Gobe, G. (2010). Protease-activated receptor-2 and renal carcinogenesis. In: 46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Perth Convention and Exhibition Centre, Perth, Western Australia, (91-91). 12-15 September 2010. doi:10.1111/j.1440-1797.2010.01377_1.x

  • Liebscher, Susan, Chappell, K. J., Stoermer, Martin J., Watterson, Daniel, Webb, Richard I., Khromykh, Alexander A., Fairlie, David P. and Young, Paul R. (2010). Sneaking up on West Nile Virus NS2B/NS3 protease subcellular activity utilising dye-quenched substrates. In: PlusStrand 2010: The Ninth International Symposium on Positive-Strand RNA Viruses, Atlanta, GA, U.S.A., (88-88). 17-21 May 2010.

  • Fairlie, David P., Madala, Praveen K., Stoermer, Martin J., Suen, Jacky, Barry, Grant and Lohman, Rink-Jan (2009). Regulating protein and peptide activated GPCRs. In: Abstracts of Papers of the American Chemical Society. , , (). .

  • Cantley, M. D., Fairlie, D. P., Bartold, M. P., Rainsford, K. D. and Haynes, D. R. (2009). Inhibition of both class I and class II histone deacetylases is required to effectively inhibit osteoclast bone resorption in vivo and in vitro. In: Bone. 2nd Joint Meeting of the International-Bone-and-Mineral-Society/Australian-New-Zealand-Bone-and-Mineral-Society, Sydney Australia, (S133-S134). Mar 21-25, 2009. doi:10.1016/j.bone.2009.01.292

  • Liebscher, S., Chappell, K.J., Stoermer, M.J., Fairlie, D.P. and Young, P.R (2009). Antiviral activity in cell culture of potent inhibitors targeting the West Nile Virus NS2B/NS3 protease. In: 6th General Meeting of the International Proteolysis Society, Gold Coast , QLD, Australia, (102-102). 26-30 October, 2009.

  • Chappell, K. J., Fairlie, D. P., Gan, C. H., Gupta, P. K., Hu, S., Jensen, C. M., Liebscher, S., Martin, J. L., Robin, G., Stoermer M. J., Xu, W. and Young, P. R. (2009). Potent inhibitors of West Nile Virus NS2B/NS3 protease. In: 6th General Meeting of the International Proteolysis Society, Gold Coast, QLD, Australia, (55-55). 26-30 October 2009.

  • Madala, P. K., Stoermer, M., Tyndall, J. D. A., Monk, P. N., Higginbottom, A. and Fairlie, D. P. (2008). COMP 264-Unraveling the mechanism of antagonism for human C5a receptor: Comparison of three structurally different antagonists. In: Abstracts of paper : American Chemical Society National Meeting. 236th National Meeting of the American Chemical Society, Philadelphia, USA, (). 17-21 August, 2008.

  • Fairlie, DP, Le, GT, Halili, M, Ruiz-Gomez, G and Abbenante, J (2008). MEDI 256-Activation and inhibition of latent serine proteases, complement factors B and C2. In: Abstracts of papers of the American Chemical Society. 236th National Meeting of the American Chemical Society, Philadelphia PA, (). 17-21 August 2008.

  • Andrews, Kathy T., Tran, Thanh N., Lucke, Andrew, Kahnberg, Pia, Lee, G. T., Skinner-Adams, Tina, Gardiner, Donald L. and Fairlie, David P. (2007). Plasmodium falciparum histone deacetylases: Enzymes involved in gene regulation as new antimalarial drug targets. In: Abstract Book: American Society of Tropical Medicine and Hygiene : 56th Annual Meeting. 56th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene, Philadelphia, PA United States, (48-48). 04-08 November 2007.

  • Beyer, Renee L., Hoang, Huy N., Le, Giang T. and Fairlie, David P. (2006). MEDI 180-Effects of cyclization constraints on helix/turn peptide structures. In: Abstracts of Papers of the American Chemical Society. , , (). .

  • Beyer, Renee L., Kelso, Michael J., Reid, Robert C., Le, Giang T. and Fairlie, David P. (2006). MEDI 181-Alpha helix induction in HIV REV34-50 by N-terminal nucleators. In: Abstracts of Papers of the American Chemical Society. , , (). .

  • Monk, Peter N., Higginbottom, Adrian, Madala, Praveen K., Tyndall, Joel D. A., Stoermer, Martin and Fairlie, David P. (2006). Defining the ligand binding site on the human C5a receptor. In: Abstracts of Papers of the American Chemical Society. 231st National Meeting of the American-Chemical-Society, Atlanta Ga, (). Mar 26-30, 2006.

  • Beyer, Renee L., Kelso, Michael J., Reid, Robert C., Le, Giang T. and Fairlie, David P. (2006). Alpha helix induction in HIV REV34-50 by N-terminal nucleators. In: Chemical Engineering News: Abstracts-232nd ACS National Meeting. 232nd ACS National Meeting, San Francisco, CA, U.S.A., (55-55). 10-14 September, 2006. doi:10.1021/cen-v084n034.p055

  • Monk, Peter N., Higginbottom, Adrian, Madala, Praveen K., Tyndall, Joel D. A., Stoermer, Martin and Fairlie, David P. (2006). Defining the ligand binding site on the human C5a receptor. In: Program report of the American Chemical Society. National Meeting. The 231st ACS National Meeting, Atlanta, GA, U.S.A., (90-90). 26-30 March 2006.

  • Desai, A., Khlentzos, A., Shepherd, N., Hoang, H. N., Letouze, E., Fairlie, D. and Young, P. R. (2006). Developing antiviral targets for RSV via mutational analysis of HRB and HRC domains using a novel fusion assay system. In: 13th International Conference of Negative Strand Viruses. 13th International Conference of Negative Strand Viruses, Salamanca, (). 17-22 June, 2006.

  • Chappell, K. J., Stoermer, M J, Fairlie, D and Young, P R (2006). Investigation of the West Nile virus NS3 protease by tandem use of site-directed mutagenesis and substrate modification. In: Australian Society for Microbiology Annual Scientific Meeting. Australian Society for Microbiology Annual Scientific Meeting, Gold Coast, Qld, (Abstract). 2-6 July, 2006.

  • Young, P. R., Chappell, K. J., Stoermer, M. J., Fairlie, D., Kampmann, T. and Kobe, B. (2006). Multiple targets for antiviral inhibitors. In: 7th Asia Pacific Congress of Virology. 7th Asia Pacific Congress of Virology, New Delhi, (Abstract). 13-15 Nov, 2006.

  • Fairlie, D. (2006). New Treatment Strategies for Dengue and other Flaviviral Diseases. In: G. Bocks and J. Goode., New Treatment Strategies for Dengue and other Flaviviral Diseases. Norvatis foundations Symposium 277 on New Treatment Strategies for Dengue and other Flaviviral Diseases, Singapore, (). 26-27 September, 2005.

  • Fairlie, D., Singh, Y. and Sharpe, P. C. (2006). Peptide bundles: Loops, helices, strands and sheets. In: Abstracts Of Papers, 231st ACS National Meeting. The American Chemical Society Meeting 2006, Atlanta, GA, USA, (). 26 -30 March, 2006.

  • Ma, M. T., Hoang, H. N., Beyer, R. L., Bryant, G. K., Appleton, T. G. and Fairlie, D. (2005). Alpha-helix induction in short peptides using metal clips. In: International Chemical Congress of Pacific Basin Societies (Pacifichem2005). International Chemical Congress of Pacific Basin Societies (Pacifichem2005), Honolulu, Hawaii, (xx-xx). 15 - 20 December 2005.

  • Chappell, K. J., Stoermer, M. J., Fairlie, D. and Young, P. R. (2005). Development of a catalytically active recombinant West Nile NS3 protease and the identification of key enzyme-substrate interactions by site-directed mutagenesis. In: 30th Lorne Conference on Protein Structure and Function. 30th Lorne Conference on Protein Structure & Function, Lorne, (Abstract). 6-10 Feb, 2005.

  • Chappell, K. J., Stoermer, M. J., Fairlie, D. and Young, P. R. (2005). Development of a catalytically active recombinant West Nile NS3 protease and the identification of key enzyme-substrate interactions by site-directed mutagenesis. In: International Congress of Virology. International Congress of Virology, San Francisco, (Abstract). 23-27 July, 2005.

  • Chappell, K. J., Stoermer, M. J., Fairlie, D. and Young, P. R. (2005). Development of a catalytically active recombinant West Nile virus NS3 protease and the identification of key enzyme-substrate and enzyme-cofactor interactions by site-directed mutagenesis. In: 3rd Australian Virology Group Meeting. 3rd Australian Virology Group Meeting, Phillip Island, Vic., (Abstract). 9-12 Dec, 2005.

  • Levick, S., Taylor, S. M., Fairlie, D. and Brown, L. C. (2004). Cardiovascular structural and functional adaptations to group IIAsPLA2 inhibition. In: R. A. Walsh and A. Smisek, XV111 World Congress of the International Society for Heart Research. 2004 ISHR World Congress, Brisbane, Australia, (272-273). 7-11/8/04.

  • Shepherd, N. E., Hoang, H., Abbenante, G. and Fairlie, D. P. (2004). Towards Modular Alpha-Helices: Comformationally Stable Cyclic Pentapeptides as Alpha-Turn Mimetics. In: Journal of Peptide Science. , , (279-279). .

  • Fairlie, DP, Singh, Y, Sharpe, P and Stoermer, M (2003). Template-assembled peptide loops, helices, sheets and nanofibres. In: Abstracts of Papers of the American Chemical Society. 225th National Meeting of the American-Chemical-Society, New Orleans Louisiana, (U322-U322). Mar 23-27, 2003.

  • Beyer, R. L., Kelso, M. J., Hoang, H. N., Appleton, T. G. and Fairlie, D. (2003). Helix inducing metal clips in short peptides. In: Baba and Y, Biomolecular Chemistry. Proceedings of the First International Symposium on Biomolecuy, Awaji, Japan, (146-149). 2-5 December, 2003.

  • Hoang, Huy N., Bryant, Gavin K., Kelso, Micheal J., Beyer, Renee L., Appleton, Trevor G. and Fairlie, David P. (2003). Short peptide alpha helices induced by multiple metal clips. In: M. Sono and J. H. Dawson, Journal of Inorganic Biochemistry. Abstracts of the 11th International Conference on Biological Inorganic Chemistry. 11th International Conference on Biological Inorganic Chemistry, Cairns, Australia, (146-146). 19-23 July 2003. doi:10.1016/S0162-0134(03)80638-4

  • Hoang, Huy N., Bryant, Gavin K., Kelso, Micheal J., Beyer, Renee L., Appleton, Trevor G. and Fairlie, David P. (2003). Short peptide alpha helices induced by multiple metal clips. In: Journal of Inorganic Biochemistry. 11th International Conference on Biological Inorganic Chemistry, Cairns, Australia, (146-146). 19-23 July, 2003. doi:10.1016/S0162-0134(03)80638-4

  • Gahan, Lawrence R., Cusack, Rodney M., Grondahl, Lisbeth H., Fairlie, David P. and Hanson, Graeme R. (2003). Studies of the interaction of potassium(I), calcium(II), magnesium(II) and copper(II) with cyclosporin A. In: Journal of Inorganic Biochemistry: Abstracts of the 11th International Conference on Biological Inorganic Chemistry. 11th International Conference on Biological Inorganic Chemistry, New York, USA, (136-136). 19-23July, 2003. doi:10.1016/S0162-0134(03)80624-4

  • Fairlie, David P ., Singh, Yogendra, Sharpe, Philip and Stoermer, Martin (2003). Template-assembled peptide loops, helices, sheets, and nanofibers. In: Abstracts of Papers, 225th ACS National Meeting. 225th ACS National Meeting, New Orleans, LA, United States, (). 23-27 March 2003.

  • Kelso, MJ, Hoang, HN, Appleton, TG and Fairlie, DP (2002). Palladium induced alpha helicity in short peptides.. In: Abstracts of Papers of the American Chemical Society. , , (B238-B238). .

  • Woodruff, T. M., Shiels, I. A., Fairlie, D. and Taylor, S. M. (2001). A new C5a receptor antagonist inhibits monoarticular arthritis in the rat. In: Proceedings of the Complement Associated Diseases, Animal Models and Therapeutics Workshop. Complement Assoc. Diseases, Animal Models & Ther. Workshop, Santorini, Greece, (37-37). 10-14 October, 2001.

  • Fang, N., Arakaki, T., Fairlie, D., Martin, J. L. and Young, P. R. (2001). Construction and characterization of the dengue 2 virus NS3 protease and its mutants. In: 1st Australian Virology Group Meeting, Fraser Island, Qld, ((Abstract)). 5-9 December, 2001.

  • Appleton, T. G., Fairlie, D., Hoang, H. N., Kelso, M., March, D. R. and Oliver, W. (2001). Control of peptide conformation by Palladium(II) coordination. In: Journal of Inorganic Biochemistry. 10th International Conf on Bioinorganic Chemistry, Florence, Italy, (86 (Abstract)-127). 26-31 August, 2001.

  • Young, P. R., Fang, N., Leung, D., Arakaki, T., Stoermer, M. J., Fairlie, D. and Martin, J. L. (2001). In vitro catalytic activity of recombinant forms of the dengue virus NS3 protease. In: 6th International Symposium on Positive Strand Viruses, Paris, France, ((Abstract)). 28 May - 2 June, 2001.

  • Appleton, T. G., Hoang, H. N., Fairlie, D., Kelso, M. and Bryant, G. K. (2001). Metal clips for folding peptides. In: World Chemistry Congress. World Chemistry Congress, Brisbane, (PG30-PG30). 1-6 July, 2001.

  • Arumugum, T.V., Shiels, I. A., Fairlie, D. and Taylor, S. M. (2001). Prevention of ischemia/reperfusion injuries in rats by a new small molecule C5a receptor antagonist. In: Proceedings of the Complement Associated Diseases, Animal Models, and Therapeutics Workshop. Complement Associated Diseases, Animal Models and Ther. W/shop, Santorini, Greece, (47-47). 10-14 October 2001.

  • Fairlie, DP (2000). Complement and inflammation: New antagonists of C5a receptors.. In: Abstracts of Papers of the American Chemical Society. , , (U63-U63). .

  • Appleton, T. G., Hoang, H. N. and Fairlie, D. (2000). Coordination with Pd(en)2+ imposes an a-helical structure on a pentapeptide. In: 2000 International Chemical Congress of Pacific Basin Societies. Pacifichem 2000, Honolulu, Hawaii, (881). 14-19 December, 2000.

  • Young, P. R., Fang, N., Leung, D., Arakaki, T., Fairlie, D. and Martin, J. L. (2000). Expression and characterization of a catalytically active form of the Dengue virus NS3 protease. In: 1st International Conference on Dengue and Dengue Haemorrhagic Fever. 1st Int Conf on Dengue and Dengue Haemorrhagic Fever, Chiang Mai, Thailand, ((Abstract)). 20-24 Nov, 2000.

  • Hanson, G. R., Bush, A. R. I., Fairlie, D. and Tyndall, J. (2000). Metallopeptides in Alzheimer's Disease. In: Brisbane Inorganic Chemsitry Symposium. Brisbane Inorganic Chemistry Symposium, Dept of Chemistry, Uni of Queensland, (10). 30 November 2000.

  • Hoang, H. N., Appleton, T. G. and Fairlie, D. (2000). The reaction between metal ions and short peptides. In: 11th National Convention of the Royal Australian Chemical Institute, Inorganic Chemistry Division Conference IC2000/11RACIC. IC2000/11RACIC, Canberra, (PM36). 6-11 Feb, 2000.

  • Cusack, R., Grondahl, L., Abbenante, J., Fairlie, D., Gahan, L. R., Hambley, T. W. and Hanson, G. R. (1999). Cyclic peptides as metal ion receptors. In: J. Spencer and A. Brodie, Abstracts of IC'99 Joint Meeting of the Inorganic Division of the RACI and Inorganic and Organometallic Specialist Group of the NZ Institute of Chemistry. IC'99, Wellington, NZ, (21). 31 January - 4 February 1999.

  • White, H., Young, P. R., Brinkworth, R. I., Fairlie, D. and Leung, D. D. (1999). Homology model of the dengue 2 virus NS3 protease: Interactions with NS2B co-factor. In: Abstract book: XIth International Congress of Virology. XIth International Congress of Virology, Sydney, (). 9-13 August 1999.

  • Appleton, T. G., Prinsep, M. R., Fairlie, D. P., Lane, I. and Hanson, G. R. (1997). The selective binding of metal ions by tolyporphins. In: Chris Orvig, Pure and Applied Chemistry. Proceedings of: 31st International Conference on Coordination Chemistry. XXXI ICCC: International Conference on Coordination Chemistry, Vancouver, BC, Canada, (). 18–23 August 1996.

  • Cusack, R. M., Abernante, J., Gahan, L. R., Fairlie, D. P. and Hanson, G. R. (1996). Cyclic Peptides as Metal Ion Receptors. In: RACI Inorganic Division, IC '96, Townsville, Queensland, Australia, (). 30 June - 4 July, 1996.

  • Abbenante, G., Fairlie, D. P., Sokolenko, N., Gahan, L. R., Cusack, R., Hanson, G. R. and Pierens, G. K. (1996). Effects of conformational constraints in cyclic octapeptides of marine origin. In: 10th Brisbane Organic Chemistry Symposium, Brisbane, QLD, Australia, (U382-U382). 29 November 1996.

  • Hanson, G. R., van den Brenk, A. L., Gahan, L. R., Fairlie, D. P. and Hawkins, C. J. (1996). Multifrequency EPR studies of the mono- and bi-nuclear copper(II) complexes formed with the marine cyclic octapeptides patellamide D and ascidiacyclamide. In: Applied Magnetic Resonance. Selected Proceedings from EPR-95. EPR-95: Electron Paramagnetic Resonance 1995 Satellite Workshop Meeting of the 12th International Society of Magnetic Resonance Conference (ISMAR'95), Sydney, NSW, Australia, (). 13-15 July 1995.

  • Lane, I., Prinsep, M., Hanson, G. R., Appleton, T. G. and Fairlie, D. (1995). Multifrequency EPR spectra of Cu(II) and Ag(II) tolyporphins. In: David G. Gorenstein, Bulletin of Magnetic Resonance: Proceedings of the International Society of Magnetic Resonance Xllth Meeting Part I. ISMAR 95: Twelfth Conference of the International Society of Magnetic Resonance, Sydney, NSW, Australia, (). 16-21 July 1995.

  • Appleton, T. G., Prinsep, M. R., Fairlie, D. P., Lane, I., Hanson, G. R. and Moore, R. E. (1995). The selective binding of tolyporphins to metal ions. In: Program Booklet: Chemistry Serving Society. RACI 10NC: Royal Australian Chemical Institute's 10th National Convention. 10th National Convention RACI: The Royal Australian Chemical Institute's 10th National Convention: Chemistry Serving Society, Adelaide, SA, Australia, (). 27 September-2 October 1995.

Other Outputs

Grants (Administered at UQ)

PhD and MPhil Supervision

Current Supervision

  • Doctor Philosophy — Principal Advisor

    Other advisors:

  • Doctor Philosophy — Principal Advisor

    Other advisors:

  • Doctor Philosophy — Principal Advisor

    Other advisors:

  • Doctor Philosophy — Principal Advisor

  • Doctor Philosophy — Principal Advisor

    Other advisors:

  • Doctor Philosophy — Principal Advisor

    Other advisors:

  • Master Philosophy — Principal Advisor

    Other advisors:

  • Doctor Philosophy — Principal Advisor

    Other advisors:

  • Doctor Philosophy — Principal Advisor

    Other advisors:

  • Doctor Philosophy — Principal Advisor

    Other advisors:

  • Doctor Philosophy — Principal Advisor

    Other advisors:

Completed Supervision